Effect of Ceftobiprole on the Intestinal Human Microflora Following Multiple-dose Administration in Healthy Female and Male Subjects.

Trial Profile

Effect of Ceftobiprole on the Intestinal Human Microflora Following Multiple-dose Administration in Healthy Female and Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2012

At a glance

  • Drugs Ceftobiprole medocaril (Primary)
  • Indications Community-acquired pneumonia; Gram-negative infections; Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections
  • Focus Pharmacodynamics
  • Sponsors Basilea Pharmaceutica; Janssen-Cilag
  • Most Recent Events

    • 27 Jul 2012 Company and lead trial centre added as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Actual patient number (12) added as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Additional locations (Belgium, Sweden) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top